177 related articles for article (PubMed ID: 34883290)
1. A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy.
Li SS; Zhang CM; Wu JD; Liu C; Liu ZP
Eur J Med Chem; 2022 Jan; 228():114037. PubMed ID: 34883290
[TBL] [Abstract][Full Text] [Related]
2. N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma.
Li T; Yu P; Chen Y; Sun B; Dong P; Zhu T; Meng X
Eur J Med Chem; 2021 Oct; 222():113605. PubMed ID: 34126457
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of novel mono- and bivalent ASGP-R-targeted drug-conjugates.
Petrov RA; Maklakova SY; Ivanenkov YA; Petrov SA; Sergeeva OV; Yamansarov EY; Saltykova IV; Kireev II; Alieva IB; Deyneka EV; Sofronova AA; Aladinskaia AV; Trofimenko AV; Yamidanov RS; Kovalev SV; Kotelianski VE; Zatsepin TS; Beloglazkina EK; Majouga AG
Bioorg Med Chem Lett; 2018 Feb; 28(3):382-387. PubMed ID: 29269214
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
5. Chamaejasmenin E from Stellera chamaejasme induces apoptosis of hepatocellular carcinoma cells by targeting c-Met in vitro and in vivo.
Yu XQ; Yan QL; Shen S; Cheng ZY; Huang XX; Yao GD; Song SJ
Bioorg Chem; 2022 Feb; 119():105509. PubMed ID: 34844768
[TBL] [Abstract][Full Text] [Related]
6. Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system.
Zhang X; Zhang X; Yu P; Han Y; Li Y; Li C
J Pharm Sci; 2013 Jan; 102(1):145-53. PubMed ID: 23132353
[TBL] [Abstract][Full Text] [Related]
7. The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging.
Li H; Du G; Yang L; Pang L; Zhan Y
Anticancer Agents Med Chem; 2020; 20(9):1147-1156. PubMed ID: 32106805
[TBL] [Abstract][Full Text] [Related]
8. Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation.
Li P; Liu Y; He Q
Drug Des Devel Ther; 2020; 14():1609-1620. PubMed ID: 32425506
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma.
Jiang S; Li M; Hu Y; Zhang Z; Lv H
Carbohydr Polym; 2018 Oct; 197():194-203. PubMed ID: 30007605
[TBL] [Abstract][Full Text] [Related]
10. Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA.
Li T; Lv M; Chen X; Yu Y; Zang G; Tang Z
Drug Des Devel Ther; 2019; 13():1289-1300. PubMed ID: 31118568
[No Abstract] [Full Text] [Related]
11. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
12. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
14. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
15. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling.
Ke X; Zhao Y; Lu X; Wang Z; Liu Y; Ren M; Lu G; Zhang D; Sun Z; Xu Z; Song JH; Cheng Y; Meltzer SJ; He S
Oncotarget; 2015 Oct; 6(32):32610-21. PubMed ID: 26416455
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the hypoxia-induced drug resistance in liver tumor by the concurrent use of apigenin and paclitaxel.
Li K; Li M; Luo Z; Mao Y; Yu Y; He Y; Zhou J; Fei Y; Pei Y; Cai K
Biochem Biophys Res Commun; 2020 May; 526(2):321-327. PubMed ID: 32220496
[TBL] [Abstract][Full Text] [Related]
18. Response Surface Methodology to Optimize the Combination Treatment of Paclitaxel, Bufalin and Cinobufagin for Hepatoma Therapy.
Zhang J; Shu C; Yi X; Zhu J; Lian X; Wu Y
Comb Chem High Throughput Screen; 2021; 24(10):1727-1735. PubMed ID: 33172373
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
20. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]